After a national shortage reached critical levels in 2019, Merck is stepping up to the plate to ramp up its production of a potent, life-saving bladder cancer drug. Merck, known as MSD outside the U.S. and Canada, announced they will construct a new manufacturing facility to significantly expand its production capacity for TICE® BCG (BCG Live for Intravesical Use).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,